DiaMedica Therapeutics (DMAC) Projected to Announce Earnings on Wednesday

Key Points

• DiaMedica Therapeutics is expected to report Q3 2026 results after market close on November 11, with analysts forecasting a $0.20-per-share loss and $13.5 million in revenue.
• In its latest reported quarter, the company posted a $0.19-per-share loss, beating the consensus estimate of a $0.20 loss by one cent.
• Analysts give DMAC a consensus “Moderate Buy” rating and an average $12 price target; the stock opened at $10.00.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect DiaMedica Therapeutics to announce earnings of ($0.20) per share and revenue of $13.50 million for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.01. On average, analysts expect DiaMedica Therapeutics to post ($0.84) EPS for the current fiscal year and ($0.81) EPS for the next fiscal year.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ:DMAC opened at $10.00 on Wednesday. DiaMedica Therapeutics has a 52 week low of $5.24 and a 52 week high of $10.42. The company has a market capitalization of $539.30 million, a PE ratio of -13.89 and a beta of 0.95. The company has a 50 day moving average price of $7.73 and a two-hundred day moving average price of $7.14.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Wall Street Zen raised shares of DiaMedica Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, October 24th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of DiaMedica Therapeutics in a research note on Thursday, October 15th. Finally, HC Wainwright reiterated a "buy" rating and set a $12.00 target price on shares of DiaMedica Therapeutics in a report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, DiaMedica Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $12.00.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases affecting the kidneys and nervous system. The company's research is centered on therapies intended to address conditions with limited treatment options.

DiaMedica's lead investigational product is DM199, a recombinant form of human tissue kallikrein-1, an enzyme involved in blood flow regulation and vascular function. The company has evaluated DM199 in clinical development programs targeting acute ischemic stroke and kidney-related diseases, including chronic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.